RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy combined with leucovorin and fluorouracil in treating patients who have undergone surgery to completely remove stage II or stage III colon cancer.

开始日期2001-03-01

申办/合作机构

Intracel Corp.

100 项与 Autologous tumor cell vaccine(Intracel Corp) 相关的临床结果

登录后查看更多信息

100 项与 Autologous tumor cell vaccine(Intracel Corp) 相关的转化医学

登录后查看更多信息

100 项与 Autologous tumor cell vaccine(Intracel Corp) 相关的专利（医药）

登录后查看更多信息

项与 Autologous tumor cell vaccine(Intracel Corp) 相关的文献（医药）

2020-09-07·The Journal of experimental medicine1区 · 医学

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

1区 · 医学

Article

作者: Maeda, Lauren S. ; Miklos, David B. ; Moore, A. Holliston ; Haabeth, Ole A.W. ; Phillips, Destiny L. ; Weng, Wen-Kai ; Chu, Michael P. ; Frank, Matthew J. ; Advani, Ranjana H. ; Faham, Malek ; Brody, Joshua D. ; Czerwinski, Debra K. ; Negrin, Robert S. ; Khodadoust, Michael S. ; Okada, Ami ; Alizadeh, Ash A. ; Wapnir, Irene L. ; Meyer, Everett H. ; Sheehan, Kevin ; Reddy, Sunil A. ; Laport, Ginna G. ; Gupta, Neel K. ; Rezvani, Andrew R. ; Levy, Ronald

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89%) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40% of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe.

2020-06-01·BMJ open4区 · 医学

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews

4区 · 医学

ArticleOA

作者: Kennedy, Michael A ; Bastin, Donald ; Fergusson, Dean A ; Diallo, Jean-Simon ; Lalu, Manoj ; Kekre, Natasha ; Auer, Rebecca C ; Forbes, Nicole ; Khan, Sarwat T ; Montroy, Joshua

Introduction:

Autologous cancer cell vaccines are promising personalised immunotherapeutic options for solid and haematological malignancies that uses the patient’s own cells to arm an immune response. Evidence suggests that among patients receiving these vaccines, those who mount an immune response against their own tumour cells have better prognosis, and a myriad of preclinical studies have demonstrated the same. Recently, two autologous cell vaccines Vigil and OncoVAX have made it to phase III clinical trials. Here, we outline a protocol to be used for two separate systematic reviews using a parallel approach for inclusion criteria, data extraction and analysis for autologous cell vaccines in (1) solid and (2) haematological malignancies. We aim to review evidence from controlled and uncontrolled interventional studies of autologous cell vaccines administered to patients with cancer to determine their historical efficacy (with or without associated adjuvants or modifications) with clinical response rates and safety outcomes being of particular importance.

Methods and analysis:

We will search MEDLINE (OVID interface, including In-Process and Epub Ahead of Print), Embase (OVID interface) and the Cochrane Central Register of Controlled Trials (Wiley interface) for articles published from 1947 until 30 July 2018 (date search was performed). Studies will be screened first by title and abstract, then by full-text in duplicate. Interventional trials that report the use of an autologous cell vaccine to patients with cancer of any age will be included. The primary outcomes of interest in this review are clinical response (complete or overall/objective response) and safety outcomes (adverse events). Secondary outcomes include immune response, disease-free survival and overall survival. The risk of bias within studies will be assessed using the appropriate Cochrane Risk of Bias tool. If appropriate, a random effects meta-analysis will be performed to synthesise the data and report summary estimates of effect. Statistical heterogeneity will be assessed using the I2 statistic.

Ethics and dissemination:

Ethics approval is not required for this systematic review protocol as the review will solely use published literature. Results will be submitted to peer-reviewed journals for publication and presented to relevant stakeholders and scientific meetings.

PROSPERO registration number:

CRD42019140187.

2012-08-01·Human vaccines & immunotherapeutics3区 · 医学

Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer

3区 · 医学

Review

作者: Hanna, Michael G

At the cellular level it is clear that cancer is a genetic disease arising as a clone that expands and grows in an unregulated manner. While it has always been presumed that neoplasia is a consequence of somatic cell mutations, only in the last few years has the magnitude and diversity of these mutations been elucidated by modern DNA sequencing technology. Immunotherapy is the premier biological approach to targeted therapy. Target therapies require targets. In this case the targets are tumor specific or associated antigens, the proteins expressed from these somatic cell mutations. While the immunotherapeutic approach to eliminating cancer was launched with the assumption that cancer cells were homogeneous, the recent genomic understanding of tumor cells indicates that there is both inter- and intra-tumoral heterogeneity. This presentation will discuss the consequences of this new knowledge of tumor cell biology to the immunotherapeutic approach to treating cancer.

100 项与 Autologous tumor cell vaccine(Intracel Corp) 相关的药物交易

登录后查看更多信息